OTC - ACTIVE INGREDIENT SECTION
allantoin
allantoin
Jeju Water, Cetearyl alcohol, Cetrimoniumchloride, Dimethicone and Laureth-23 and Laureth-3, SOYAMIDE DEA QUATERNIUM-52 POLYQUATERNIUM-11 MAGNESIUM NITRATE MAGNESIUM CHLORIDE, Glyceryl Stearate SE, PEG-10 Sorbitan Laurate , Acrus Calamus Root Extrct, Lawsonia Inermis Extract, Kumsong Extract, Sophora Flavescens Root Extract, Angelica Gigas Root Extract, Soluble Seaweed Extract, Glycyrrhiza Glabra (Licorice)Root Extract, Witch Hazel Extract, Espinosilla Extract, Red Ginseng Extract, Duchesnea Indica Fruit Extract, Sodium Cocoyl Hydrolyzed Wheat Protein, Polyquaternium 10, Camellia Japonica Seed Oil, D-Panthenol, Allantoin, Hydrolyzed Silk, Sodium Hyaluronate, Tocopheryl Acetate, Rosmarinus Officinalis, Disodium EDTA, Perfume, Zanthoxylum Pieperitum Fruit Extract, Pulsatilla Koreana Extract, Usnea Barbata Root Extract
supplying moisture and nutrient to scalp and hair
keep out of reach of the children
after shampooing, work evenly into wet hair with fingertips, paying special attention to ends or damaged areas
rinse thoroughly
stop use if irritation occurs
avoid contact with eyes
for external use only
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | EAN-13 | 8809380400040 | GTIN-13: 8809380400040 EAN-13: 8809380400040 GTIN storage (14 digits): 08809380400040 | label.jpg |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 60344-6001-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-7615-f424-e053-dadaa90a57ce | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 60344-6001-1 | Queen Perfume Hair Conditioner | 355 mL in 1 BOTTLE | LIQUID | 355 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 60344-6001 | QUEEN PERFUME HAIR CONDITIONER (ALLANTOIN) LIQUID [TAMNAMO CO., LTD] | 1 | Legacy NDC, 1 package rows | 20140130_208d0487-3bba-468c-8e62-07d695b17c6a.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ALLANTOIN | ACTIVE INGREDIENT | 344S277G0Z | 1 | |
| ALLANTOIN | ACTIVE MOIETY | 344S277G0Z | 1 | |
| ANGELICA GIGAS ROOT | INACTIVE INGREDIENT | 32766B2FHX | 1 | |
| CETOSTEARYL ALCOHOL | INACTIVE INGREDIENT | 2DMT128M1S | 1 | |
| GLYCERYL MONOSTEARATE | INACTIVE INGREDIENT | 230OU9XXE4 | 1 | |
| GLYCYRRHIZA GLABRA | INACTIVE INGREDIENT | 2788Z9758H | 1 | |
| HYALURONATE SODIUM | INACTIVE INGREDIENT | YSE9PPT4TH | 1 | |
| SOPHORA FLAVESCENS ROOT | INACTIVE INGREDIENT | IYR6K8KQ5K | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 60344-6001 | 60344-6001-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| ALLANTOIN | 344S277G0Z | ACTIB |
| CETOSTEARYL ALCOHOL | 2DMT128M1S | IACT |
| GLYCERYL MONOSTEARATE | 230OU9XXE4 | IACT |
| SOPHORA FLAVESCENS ROOT | IYR6K8KQ5K | IACT |
| ANGELICA GIGAS ROOT | 32766B2FHX | IACT |
| GLYCYRRHIZA GLABRA | 2788Z9758H | IACT |
| HYALURONATE SODIUM | YSE9PPT4TH | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | CAPSULE / ORAL | 13.75 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET / ORAL | 33.34 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | AEROSOL, FOAM / TOPICAL | 3.27 %w/w | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | SUPPOSITORY / RECTAL | 35 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | LIQUID / TOPICAL | 1 %w/w | ||
| HYALURONATE SODIUM | SODIUM HYALURONATE | YSE9PPT4TH | INJECTION, SUSPENSION / INTRAVITREAL | 23 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | CAPSULE, DELAYED RELEASE / ORAL | 15 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | GRANULE, FOR SUSPENSION / ORAL | 4 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | OINTMENT / TOPICAL | 258 mg | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | TABLET, EXTENDED RELEASE / ORAL | 800 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | CAPSULE, EXTENDED RELEASE / ORAL | 32.4 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | SUSPENSION / AURICULAR (OTIC) | 0.5 %w/v | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET / SUBLINGUAL | 1.23 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET, EXTENDED RELEASE / ORAL | 529 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | AEROSOL, FOAM / VAGINAL | 3 %w/w | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | AEROSOL, FOAM / TOPICAL | 82 mg | ||
| HYALURONATE SODIUM | SODIUM HYALURONATE | YSE9PPT4TH | INJECTION, SUSPENSION / INTRAMUSCULAR | 23 mg | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | CREAM / VAGINAL | 6 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | CREAM / TOPICAL | 836 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | EMULSION / ORAL | NA | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | CREAM / VAGINAL | 140 mg | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | CAPSULE, EXTENDED RELEASE / ORAL | 9.43 mg | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | SPRAY / TOPICAL | 1 %w/w | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | SUPPOSITORY / VAGINAL | NA | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 23 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET, DELAYED RELEASE / ORAL | 6 mg | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | LOTION / TOPICAL | 3627 mg | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | OINTMENT / TOPICAL | 1.2 %w/w | ||
| HYALURONATE SODIUM | SODIUM HYALURONATE | YSE9PPT4TH | LOTION / TOPICAL | 0.01 %w/w | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | CREAM / TOPICAL | 1428 mg | ||
| HYALURONATE SODIUM | SODIUM HYALURONATE | YSE9PPT4TH | GEL / TOPICAL | 463 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET, CHEWABLE / ORAL | 1 mg | ||
| HYALURONATE SODIUM | SODIUM HYALURONATE | YSE9PPT4TH | INJECTION, SUSPENSION / INTRA-ARTICULAR | 23 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | SUSPENSION / OPHTHALMIC | 0.5 %w/v | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | LOTION / TOPICAL | 177 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ca52cb6a-4b3f-4b34-965d-36e7b3efd12d | 208d0487-3bba-468c-8e62-07d695b17c6a | 2014-01-30 | Warnings | ca52cb6a-4b3f-4b34-965d-36e7b3efd12d 208d0487-3bba-468c-8e62-07d695b17c6a |
Adverse event summaries are temporarily unavailable. Other product information remains available.